Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Hahn NM, O'Donnell MA, Efstathiou JA, Zahurak M, Rosner GL, Smith J, et al. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. Eur Urol. 2023;83(6):486-494.

Marinoff AE, Spurr LF, Fong C, Li YY, Forrest SJ, Ward A, et al. Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO Precis Oncol. 2023;7:e2200334.

Callum J, Bégin P, Jamula E, Liu Y, Kron AT, Auclair M-, et al. Lessons learned from the CONCOR-1 trial. Transfus Med. 2023;33(1):21-25.

Baillargeon D, Greenblatt M, Côté M, Nadeau M, Couture C-, Hould F-, et al. Prevalence of Helicobacter pylori Infection in Bariatric Surgery Patients. Obes Surg. 2023;33(7):2132-2138.

Zhang T, Li S, Tan YA, Na JH, Chen Z, Damle P, et al. Bcl-xL is translocated to the nucleus via CtBP2 to epigenetically promote metastasis. bioRxiv. 2023.

Rubinstein PG, Moore PC, Bimali M, Lee JY, Rudek MA, Chadburn A, et al. Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial. Lancet Haematol. 2023;10(8):e624-e632.

Priest K, Le A, Gebregzabheir A, Nijmeh H, Reis GB, Mandell M, et al. Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway. NPJ Precis Oncol. 2023;7(1):9.

Liu L, Yang HS, Xu Z, Meng L, Lu Y, Han L, et al. Explore the impact of abnormal coagulation test results on pregnancy complications and perinatal outcomes by establishing the trimester-specific reference intervals of singleton and twin pregnancies. Clin Chim Acta. 2023;541:117265.

2022

Han J, Russo G, Stratman S, Psomadakis CE, Rigo R, Owji S, et al. Toxic epidermal necrolysis-like linear IgA bullous dermatosis after third Moderna COVID-19 vaccine in the setting of oral terbinafine. JAAD Case Rep. 2022;24:101-104.

Nascimento J, Mariot C, Vianna DR, Kliemann LM, Chaves PS, Loda M, et al. Fatty acid synthase as a potential new therapeutic target for cervical cancer. An Acad Bras Cienc. 2022;94(2):e20210670.